Table 2 All Grade AEs in ≥10% of patients regardless of attribution to navoximod
|  | Navoximod 50 mg BID (n = 1) | Navoximod 100 mg BID (n = 3) | Navoximod 200 mg BID (n = 3) | Navoximod 400 mg BID (n = 3) | Navoximod 600 mg BID (n = 3) | Navoximod 800 mg BID (n = 6) | All Patients 21/28 day schedule (N = 19) | Navoximod continuous schedule 600 mg BID (n = 3) | All Patients (N = 22) |
|---|---|---|---|---|---|---|---|---|---|
Any adverse event | 1 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 6 (100%) | 19 (100%) | 3 (100%) | 22 (100%) |
Fatigue | 1 (100%) | 2 (67%) | 3 (100%) | 1 (33%) | 1 (33%) | 3 (50%) | 11 (58%) | 2 (67%) | 13 (59%) |
Cough | 1 (100%) | 3 (100%) | – | – | 1 (33%) | 4 (67%) | 9 (47%) | – | 9 (40%) |
Decreased appetite | 1 (100%) | 2 (67%) | 3 (100%) | – | – | 3 (50%) | 9 (47%) | – | 9 (40%) |
Pruritus | – | 2 (67%) | 2 (67%) | 1 (33%) | 2 (67%) | 1 (17%) | 8 (42%) | 1 (33%) | 9 (40%) |
Nausea | 1 (100%) | 3 (100%) | – | 1 (33%) | 1 (33%) | 2 (67%) | 8 (42%) | – | 8 (36%) |
Vomiting | – | 1 (33%) | 1 (33%) | 1 (33%) | 1 (33%) | 1 (17%) | 5 (26%) | 1 (33%) | 6 (27%) |
Anxiety | 1 (100%) | 1 (33%) | 1 (33%) | – | – | 1 (17%) | 4 (21%) | – | 4 (18%) |
AST increased | – | – | 1 (33%) | 1 (33%) | – | 2 (33%) | 4 (21%) | – | 4 (18%) |
Constipation | – | – | 2 (67%) | – | – | 2 (33%) | 4 (21%) | – | 4 (18%) |
Dyspepsia | – | – | 2 (67%) | 2 (67%) | – | – | 4 (21%) | – | 4 (18%) |
Dyspnea | 1 (100%) | 1 (33%) | – | – | – | 2 (33%) | 4 (21%) | – | 4 (18%) |
Wheezing | 1 (100%) | 1 (33%) | – | – | 1 (33%) | 1 (17%) | 4 (21%) | – | 4 (18%) |
Rash terms a | – | 1 (33%) | – | 1 (33%) | 1 (33%) | 1 (33%) | 4 (21%) | 1 (33%) | 5 (23%) |
Abdominal pain | – | 2 (67%) | – | – | – | 1 (17%) | 3 (16%) | 1 (33%) | 4 (18%) |
Hypokalemia | 1 (100%) | – | – | – | 1 (33%) | 1 (17%) | 3 (16%) | 1 (33%) | 4 (18%) |
Ascites | – | – | – | 1 (33%) | 1 (33%) | 1 (17%) | 3 (16%) | – | 3 (14%) |
Neoplasm progression | – | – | 1 (33%) | 1 (33%) | 1 (33%) | – | 3 (16%) | – | 3 (14%) |
Upper respiratory tract infection | – | 1 (33%) | 1 (33%) | – | – | 1 (17%) | 3 (16%) | – | 3 (14%) |
Dry mouth | – | – | – | – | 2 (67%) | – | 2 (11%) | 1 (33%) | 3 (14%) |